MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- DMC Completes Final Review of Phase 3 Heart Failure Trial
- CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
- CHF P3 Trial Accrues Sufficient Primary Endpoint Events
- MSB Provides Q1 Financial Results and Operational Highlights
- MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
Later from Mesoblast
- Appendix 4C - quarterly
- Mesoblast Submits Completed BLA for Ryoncil to US FDA
- Mesoblast Provides Half Year Results and Corporate Update
- Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
- FDA Accepts BLA for RYONCIL and Agrees to Priority Review
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast